Company profile: Amylyx Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of solutions for Alzheimer’s and other brain diseases, offering ALS treatments such as RELYVRIO (U.S.)/ALBRIOZA (Canada) and AMX0035, a combination of sodium phenylbutyrate and taurursodiol studied for ALS and other neurodegenerative diseases, plus a patient support program with assistance and a free drug program for eligible patients.
Products and services
- AMX0035: Combination-based therapy of sodium phenylbutyrate and taurursodiol, studied for potential treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases, supporting evaluation of efficacy across multiple neurodegenerative indications
- Patient Support Program: Eligibility-based assistance for patients using RELYVRIO, including a free drug program for eligible patients, delivering support services to aid therapy use and continuity
- RELYVRIO/ALBRIOZA: ALS-targeted therapeutic intended for patients with amyotrophic lateral sclerosis, known as RELYVRIO in the U.S. and ALBRIOZA in Canada, offering condition-specific treatment access for ALS management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amylyx Pharmaceuticals
Titan Pharmaceuticals
HQ: United States
Website
- Description: Provider of proprietary therapeutics and subdermal implant drug delivery solutions targeting serious medical disorders. Offerings include ProNeura, a continuous, long-term subdermal delivery platform for chronic conditions; Probuphine, a buprenorphine implant for maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less of oral buprenorphine daily; and a nalmefene implant to prevent relapse after detoxification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Titan Pharmaceuticals company profile →
Roxro Pharma
HQ: United States
Website
- Description: Provider of intranasal pain-treatment drugs, offering ROX-888 for dental and postoperative pain and ROX-828, a non-opioid, non-triptan intranasal therapy for migraine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roxro Pharma company profile →
Knopp Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage small-molecule treatments, including dexpramipexole for eosinophilic asthma and a Kv7 platform for epilepsy and other hyperexcitability disorders; engaged in drug discovery and development for neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Knopp Biosciences company profile →
Adamas Pharma
HQ: United States
Website
- Description: Provider of controlled and extended-release combination therapeutics for infectious diseases and central nervous system disorders, including products for symptomatic treatment of dementia. Offerings include Qelbree for ADHD; Trokendi XR and Oxtellar XR for epilepsy and migraine prevention; and candidates SPN-830 (hypomobility in Parkinson’s disease), SPN-820/821 (treatment-resistant depression), SPN-817 (severe epilepsy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adamas Pharma company profile →
Mission Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule therapeutics targeting deubiquitylating enzymes to enhance mitophagy and remove dysfunctional mitochondria for the treatment of cancer, acute kidney injury, and other diseases. Offerings include MTX325 (CNS-penetrant USP30 inhibitor), MTX652 (peripheral USP30 inhibitor), a proprietary DUB platform, and USP30 inhibitor programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mission Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amylyx Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amylyx Pharmaceuticals
2.2 - Growth funds investing in similar companies to Amylyx Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amylyx Pharmaceuticals
4.2 - Public trading comparable groups for Amylyx Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →